Table 2.

Recurrence risk of aHUS after kidney transplantation in the preeculizumab era.

High (RR 80–90%)	- Previous recurrence - Pathogenic mutations in CFH - CFH/CFHR1 hybrid genes. >80 of recurrence rate. High graft loss risk (45, 114) - CFB > 80% of recurrence risk - TBHD = 80% (46, 47)
Moderate (RR 40–75%)	- Isolated CFI mutations. 40–60% recurrence risk (11, 39, 41, 44) - C3. 30–70%* - Detectable circulating Anti–CFH antibodies (48–50) - Two at risk CFH haplotypes (39) - Negative complement genetic study 30% (11) - Complement gene mutation of unknown significance
Low (RR <20%)	- Isolated MCP mutation+(41) - DGKε mutation (13) - Negative Anti–CFH antibodies at the time of transplantation (48–50)

^*Recurrence risk varies depending on the different series.

⁺Recurrences in patients with MCP account for patient with combined mutation/risk polimorphisms.

RR, recurrence risk; CFH, complement factor H; CFHR1 complement factor H related protein 1; CFB, complement factor B; TBHD, thrombomodulin; CFI, complement factor I; MCP, membrane cofactor protein; DGKε, diacylglycerol kinase epsilon.